Physician profile
Anna Koget
NPI 1750607404
$9,260.74
in general payments reported to CMS, 2019-2025
14 companies · $5,351 in 2025
The $5,351 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2023: $3,708 · 2024: $16.25 · 2025: $5,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,929 · Travel and Lodging: $1,433 · Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,928.50 |
| Travel and Lodging | $1,433.16 |
| Food and Beverage | $714.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $6,957.87 | 2023-2025 | |
| Celgene Corporation | $1,950.99 | 2023-2025 | Reblozyl |
| Seagen INC. | $94.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $72.16 | 2019 | |
| Adaptive Biotechnologies Corporation | $49.74 | 2025 | Clonoseq |
| Incyte Corporation | $26.46 | 2025 | Niktimvo |
| Blueprint Medicines Corporation | $20.00 | 2025 | Ayvakit |
| Kite Pharma, INC. | $19.41 | 2025 | Yescarta |
| Genzyme Corporation | $19.20 | 2023 | |
| Novo Nordisk INC | $18.46 | 2019 | |
| Pfizer INC. | $16.25 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.20 | 2023 | Libtayo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Koget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.